BioMarin Pharmaceutical gets grant for treatment of adolescent PKU patients using avpal variant
Reduce blood phenylalanine levels in adolescents with PKU using AvPAL variants. A detailed patent outlines a method involving weekly doses over 50 weeks for subjects aged 12-17, with dosage adjustments for optimal results.
Reduce blood phenylalanine levels in adolescents with PKU using AvPAL variants. A detailed patent outlines a method involving weekly doses over 50 weeks for subjects aged 12-17, with dosage adjustments for optimal results.
What's Your Reaction?
